Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof

1. A compound of Formula I:

or a stereoisomer, pharmaceutically acceptable salt, or tautomeric form thereof; wherein:

a is N or CR 3 ;

b is N or CR 4 ;

c is N or CR 5 ;

d is N or CR 6 ;

and from 0 to 2 of a, b, c and d are N;

R 1 is selected from the group consisting of hydrogen, halogen, C 1-6 alkyl, C 3-7 cycloalkyl, —O—C 1-6 alkyl, —O—C 3-7 cycloalkyl, —C(O)OR 8 , —C(O)NR 9 R 10 and —NR 9 C(O)R 11 ; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ;

R 2 is aryl or heteroaryl; wherein each R 2′ is optionally substituted by one or more R 12 ;

R 3 , R 4 , R 5 and R 6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C 1-6 alkyl, C 3-7 cycloalkyl, —O—C 1-6 alkyl, —O—C 3-7 cycloalkyl, —CN, —NO 2 , —NR 9 R 10 , —C(O)OR 8 , —C(O)NR 9 R 10 , —NR 9 C(O)R 11 , —S(O 2 )NR 9 R 10 , —NR 9 S(O 2 )R 11 , —S(O)R 11 , —S(O 2 )R 11 , tetrazole and oxadiazole; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ;

R 8 is selected from the group consisting of hydrogen, C 1-6 alkyl, and C 3-7 cycloalkyl; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ;

R 9 and R 10 are independently selected from the group consisting of hydrogen, C 1-6 alkyl and C 3-7 cycloalkyl; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ; or

R 9 and R 10 when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members;

R 11 is selected from the group consisting of C 1-6 alkyl and C 3-7 cycloalkyl; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ; and

R 12 is selected from the group consisting of halogen, C 1-6 alkyl, —O—C 1-6 alkyl, —S—C 1-6 alkyl, C 3-7 cycloalkyl, —O—C 3-7 cycloalkyl, —C(O)OR 8 , —C(O)NR 9 R 10 , —NR 9 C(O)R 11 , —S(O 2 )NR 9 R 10 , —NR 9 S(O 2 )R 11 , —S(O)R 11 and —S(O 2 )R 11 ; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 .

2. A compound according to claim 1 , of Formula Ia:

or a pharmaceutically acceptable salt thereof; wherein:

R 1 is selected from the group consisting of hydrogen, halogen, C 1-6 alkyl, C 3-7 cycloalkyl, —O—C 1-6 alkyl, —O—C 3-7 cycloalkyl, —C(O)OR 8 , —C(O)NR 9 R 10 and —NR 9 C(O)R 11 ; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ;

R 2 is aryl or heteroaryl; wherein each R 2 is optionally substituted by one or more R 12 ;

R 3 , R 4 , R 5 and R 6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C 1-6 alkyl, C 3-7 cycloalkyl, —O—C 1-6 alkyl, —O—C 3-7 cycloalkyl, —CN, —NO 2 , —NR 9 R 10 , —C(O) OR 8 , —C(O)NR 9 R 10 , —NR 9 C(O)R 11 , —S(O 2 )NR 9 R 10 , —NR 9 S(O 2 )R 11 , —S(O)R 11 , —S(O 2 )R 11 , tetrazole and oxadiazole; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ;

R 8 is selected from the group consisting of hydrogen, C 1-6 alkyl, and C 3-7 cycloalkyl; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ;

R 9 and R 10 are independently selected from the group consisting of hydrogen, C 1-6 alkyl and C 3-7 cycloalkyl; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ; or

R 9 and R 10 when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members;

R 11 is selected from the group consisting of C 1-6 alkyl and C 3-7 cycloalkyl; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ; and

R 12 is selected from the group consisting of halogen, C 1-6 alkyl, —O—C 1-6 alkyl, —S—C 1-6 alkyl, C 3-7 cycloalkyl, —O—C 3-7 cycloalkyl, —C(O)OR 8 , —C(O)NR 9 R 10 , —NR 9 C(O)R 11 , —S(O 2 )NR 9 R 10 , —NR 9 S(O 2 )R 11 , —S(O)R 11 and —S(O 2 )R 11 ; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 .

3. A compound according to claim 1 , of Formula Ib:

or a pharmaceutically acceptable salt thereof; wherein:

R 1 is selected from the group consisting of hydrogen, halogen, C 1-6 alkyl, C 3-7 cycloalkyl, —O—C 1-6 alkyl, —O—C 3-7 cycloalkyl, —C(O)OR 8 , —C(O)NR 9 R 10 and —NR 9 C(O)R 11 ; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ;

R 2 is aryl or heteroaryl; wherein each R 2 is optionally substituted by one or more R 12 ;

R 3 , R 4 and R 5 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C 1-6 alkyl, C 3-7 cycloalkyl, —O—C 1-6 alkyl, —O—C 3-7 cycloalkyl, —CN, —NO 2 , —NR 9 R 10 , —C(O)OR 8 , —C(O)NR 9 R 10 , —NR 9 C(O)R 11 , —S(O 2 )NR 9 R 10 , —NR 9 S(O 2 )R 11 , —S(O)R 11 , —S(O 2 )R 11 , tetrazole and oxadiazole; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ;

R 8 is selected from the group consisting of hydrogen, C 1-6 alkyl, and C 3-7 cycloalkyl; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ;

R 9 and R 10 are independently selected from the group consisting of hydrogen, C 1-6 alkyl and C 3-7 cycloalkyl; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ; or

R 9 and R 10 when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members;

R 11 is selected from the group consisting of C 1-6 alkyl and C 3-7 cycloalkyl; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ; and

R 12 is selected from the group consisting of halogen, C 1-6 alkyl, —O—C 1-6 alkyl, —S—C 1-6 alkyl, C 3-7 cycloalkyl, —O—C 3-7 cycloalkyl, —C(O)OR 8 , —C(O)NR 9 R 10 , —NR 9 C(O)R 11 , —S(O 2 )NR 9 R 10 , —NR 9 S(O 2 )R 11 , —S(O)R 11 and —S(O 2 )R 11 ; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 .

4. A compound according to claim 1 , of Formula Ic:

or a pharmaceutically acceptable salt thereof; wherein:

R 1 is selected from the group consisting of hydrogen, halogen, C 1-6 alkyl, C 3-7 cycloalkyl, —O—C 1-6 alkyl, —O—C 3-7 cycloalkyl, —C(O)OR 8 , —C(O)NR 9 R 10 and —NR 9 C(O)R 11 ; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ;

R 2 is aryl or heteroaryl; wherein each R 2 is optionally substituted by one or more R 12 ;

R 3 , R 4 and R 6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C 1-6 alkyl, C 3-7 cycloalkyl, —O—C 1-6 alkyl, —O—C 3-7 cycloalkyl, —CN, —NO 2 , —NR 9 R 10 , —C(O)OR 8 , —C(O)NR 9 R 10 , —NR 9 C(O)R 11 , —S(O 2 )NR 9 R 10 , —NR 9 S(O 2 )R 11 , —S(O)R 11 , —S(O 2 )R 11 , tetrazole and oxadiazole; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ;

R 8 is selected from the group consisting of hydrogen, C 1-6 alkyl, and C 3-7 cycloalkyl; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ;

R 9 and R 10 are independently selected from the group consisting of hydrogen, C 1-6 alkyl and C 3-7 cycloalkyl; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ; or

R 9 and R 10 when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members;

R 11 is selected from the group consisting of C 1-6 alkyl and C 3-7 cycloalkyl; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ; and

R 12 is selected from the group consisting of halogen, C 1-6 alkyl, —O—C 1-6 alkyl, —S—C 1-6 alkyl, C 3-7 cycloalkyl, —O—C 3-7 cycloalkyl, —C(O)OR 8 , —C(O)NR 9 R 10 , —NR 9 C(O)R 11 , —S(O 2 )NR 9 R 10 , —NR 9 S(O 2 )R 11 , —S(O)R 11 and —S(O 2 )R 11 ; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 .

5. A compound according to claim 1 , of Formula Id:

or a pharmaceutically acceptable salt thereof; wherein:

R 1 is selected from the group consisting of hydrogen, halogen, C 1-6 alkyl, C 3-7 cycloalkyl, —O—C 1-6 alkyl, —O—C 3-7 cycloalkyl, —C(O)OR 8 , —C(O)NR 9 R 10 and —NR 9 C(O)R 11 ; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ;

R 2 is aryl or heteroaryl; wherein each R 2 is optionally substituted by one or more R 12 ;

R 3 , R 5 and R 6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C 1-6 alkyl, C 3-7 cycloalkyl, —O—C 1-6 alkyl, —O—C 3-7 cycloalkyl, —CN, —NO 2 , —NR 9 R 10 , —C(O)OR 8 , —C(O)NR 9 R 10 , —NR 9 C(O)R 11 , —S(O 2 )NR 9 R 10 , —NR 9 S(O 2 )R 11 , —S(O)R 11 , —S(O 2 )R 11 , tetrazole and oxadiazole; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ;

R 8 is selected from the group consisting of hydrogen, C 1-6 alkyl, and C 3-7 cycloalkyl; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ;

R 9 and R 10 are independently selected from the group consisting of hydrogen, C 1-6 alkyl and C 3-7 cycloalkyl; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ; or

R 9 and R 10 when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members;

R 11 is selected from the group consisting of C 1-6 alkyl and C 3-7 cycloalkyl; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ; and

R 12 is selected from the group consisting of halogen, C 1-6 alkyl, —O—C 1-6 alkyl, —S—C 1-6 alkyl, C 3-7 cycloalkyl, —O—C 3-7 cycloalkyl, —C(O)OR 8 , —C(O)NR 9 R 10 , —NR 9 C(O)R 11 , —S(O 2 )NR 9 R 10 , —NR 9 S(O 2 )R 11 , —S(O)R 11 and —S(O 2 )R 11 ; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 .

6. A compound according to claim 1 , of Formula Ie:

or a pharmaceutically acceptable salt thereof; wherein:

R 1 is selected from the group consisting of hydrogen, halogen, C 1-6 alkyl, C 3-7 cycloalkyl, —O—C 1-6 alkyl, —O—C 3-7 cycloalkyl, —C(O)OR 8 , —C(O)NR 9 R 10 and —NR 9 C(O)R 11 ; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ;

R 2 is aryl or heteroaryl; wherein each R 2 is optionally substituted by one or more R 12 ;

R 4 , R 5 and R 6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C 1-6 alkyl, C 3-7 cycloalkyl, —O—C 1-6 alkyl, —O—C 3-7 cycloalkyl, —CN, —NO 2 , —NR 9 R 10 , —C(O)OR 6 , —C(O)NR 9 R 10 , —NR 9 C(O)R 11 , —S(O 2 )NR 9 R 10 , —NR 9 S(O 2 )R 11 , —S(O)R 11 , —S(O 2 )R 11 , tetrazole and oxadiazole; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ;

R 8 is selected from the group consisting of hydrogen, C 1-6 alkyl, and C 3-7 cycloalkyl; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ;

R 9 and R 10 are independently selected from the group consisting of hydrogen, C 1-6 alkyl and C 3-7 cycloalkyl; wherein each C 3-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ; or

R 9 and R 10 when attached to the same nitrogen atom are combined to form a 3- to 7-membered ring having from 0 to 2 additional heteroatoms as ring members;

R 11 is selected from the group consisting of C 1-6 alkyl and C 3-7 cycloalkyl; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 ; and

R 12 is selected from the group consisting of halogen, C 1-6 alkyl, —O—C 1-6 alkyl, —S—C 1-6 alkyl, C 3-7 cycloalkyl, —O—C 3-7 cycloalkyl, —C(O)OR 8 , —C(O)NR 9 R 10 , —NR 9 C(O)R 11 , —S(O 2 )NR 9 R 10 , —NR 9 S(O 2 )R 11 , —S(O)R 11 and —S(O 2 )R 11 ; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl and C 3-7 cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —C 1-3 alkyl, —O—C 1-3 alkyl, —CF 3 , —CH 2 CF 3 , and —O—CF 3 .

7. A compound according to claim 1 , wherein R 2 is selected from the group consisting of phenyl

1,3-benzodioxolyl

2-pyridinyl

3-pyridinyl

4-pyridinyl

and 5-pyrimidinyl

wherein each R 2 is optionally substitute by n or more R 12 .

8. A compound according to claim 1 , selected from the group consisting of:

2

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)- 2-methyl-1H-indol-3-yl)-N,N- dimethylbenzenesulfonamide

4

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1-yl)- 2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)- N,N-dimethylbenzenesulfonamide

5

(Z)-methyl 1-(4-amino-2-fluorobut-2-en- 1-yl)-3-(3-(N,N- dimethylsulfamoyl)phenyl)-2-methyl-1H- indole-5-carboxylate

6

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)-3- (3-(N,N-dimethylsulfamoyl)phenyl)- N,N,2-trimethyl-1H-indole-5- carboxamide

7

(Z)-methyl 1-(4-amino-2-fluorobut-2-en- 1-yl)-3-(3-(N,N- dimethylsulfamoyl)phenyl)-2-methyl-1H- indole-6-carboxylate

8

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)-3- (3-(N,N-dimethylsulfamoyl)phenyl)-2- methyl-1H-indole-5-carboxylic acid

10

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)-3- (3-(N,N-dimethylsulfamoyl)phenyl)- N,N,2-trimethyl-1H-indole-6- carboxamide

11

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)-3- (3-(N,N-dimethylsulfamoyl)phenyl)-2- methyl-1H-indole-6-carboxamide

12

(Z)-ethyl 1-(4-amino-2-fluorobut-2-en-1- yl)-3-(3-(N,N- dimethylsulfamoyl)phenyl)-2-methyl-1H- indole-5-carboxylate

13

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)-3- (3-(N,N-dimethylsulfamoyl)-2- methylphenyl)-2-methyl-1H-indole-5- carboxylic acid

14

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)-2- methyl-3-(3-(methylsulfonyl)phenyl)-1H- indole-5-carboxylic acid

15

(Z)-ethyl 1-(4-amino-2-fluorobut-2-en-1- yl)-3-(3-(dimethylcarbamoyl)phenyl)-2- methyl-1H-indole-5-carboxylate

16

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)-3- (3-(dimethylcarbamoyl)phenyl)-2- methyl-1H-indole-5-carboxylic acid

17

(Z)-ethyl 1-(4-amino-2-flluorobut-2-en-1- yl)-2-methyl-3-(3- (methylsulfonyl)phenyl)-1H-indole-5- carboxylate

18

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)-2- methyl-3-(3-(N- methylsulfamoyl)phenyl)-1H-indole-5- carboxylic acid

19

(Z)-ethyl 1-(4-amino-2-fluorobut-2-en-1- yl)-3-(5-(N,N-dimethylsulfamoyl)-2- methylphenyl)-2-methyl-1H-indole-5- carboxylate

20

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)-3- (5-(N,N-dimethylsulfamoyl)-2- methylphenyl)-2-methyl-1H-indole-5- carboxylic acid

21

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)-3- (3-(N,N-dimethylsulfamoyl)phenyl)-6- fluoro-2-methyl-1H-indole-5-carboxylic acid

22

(Z)-ethyl 1-(4-amino-2-fluorobut-2-en-1- yl)-3-(3-(N,N- dimethylsulfamoyl)phenyl)-6-fluoro-2- methyl-1H-indole-5-carboxylate

25

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-2-methyl-1H-pyrrolo[3,2- b]pyridin-3-yl)-N,N- dimethylbenzenesulfonamide

26

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-2-methyl-1H-pyrrolo[3,2- c]pyridin-3-yl)-N,N- dimethylbenzenesulfonamide

29

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-2-methyl-5-(2H-tetrazol-5-yl)-1H- indol-3-yl)-N,N- dimethylbenzenesulfonamide

32

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-2-methyl-1H-pyrrolo[2,3- c]pyridin-3-yl)-N,N- dimethylbenzenesulfonamide

35

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)- 3-(3-(N,N-dimethylsulfamoyl)phenyl)- N-isopropyl-2-methyl-1H-indole-5- carboxamide

36

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)- 3-(3-(N,N-dimethylsulfamoyl)phenyl)- N-isopropyl-N,2-dimethyl-1H-indole- 5-carboxamide

37

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-5-hydroxy-2-methyl-1H-indol-3- yl)-N,N-dimethylbenzenesulfonamide

38

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)- 2-methyl-3-(3-(N- methylmethylsulfonamido)phenyl)- 1H-indole-5-carboxylic acid

39

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)- N,N,2-trimethyl-3-(3-(N- methylmethylsulfonamide)phenyl)- 1H-indole-5-carboxamide

40

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)- 3-(5-(N,N-dimethylsulfamoyl)pyridin- 3-yl)-2-methyl-1H-indole-5-carboxylic acid

41

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)- 3-(5-(N,N-dimethylsulfamoyl)pyridin- 3-yl)-N,N,2-trimethyl-1H-indole-5- carboxamide

42

(Z)-ethyl 1-(4-amino-2-fluorobut-2-en- 1-yl)-3-(3-(N,N- dimethylsulfamoyl)phenyl)-2-methyl- 1H-pyrrolo[3,2-b]pyridine-5- carboxylate

43

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)- 3-(3-(N,N-dimethylsulfamoyl)phenyl)- 2-methyl-1H-pyrrolo[3,2-b]pyridine-5- carboxylic acid

44

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)- 3-(3-(N,N-dimethylsulfamoyl)phenyl)- N,N,2-trimethyl-1H-pyrrolo[3,2- b]pyridine-5-carboxylate

45

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)- 3-(3-(N,N-dimethylsulfamoyl)phenyl)- N-isopropyl-2-methyl-1H-pyrrolo[3,2- b]pyridine-5-carboxamide

46

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)- 3-(3-(N,N-dimethylsulfamoyl)phenyl)- N,2-dimethyl-1H-pyrrolo[3,2- b]pyridine-5-carboxamide

49

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-5-methoxy-2-methyl-1H-indol-3- yl)-N,N-dimethylbenzenesulfonamide

50

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)- N,N,2-trimethyl-3-(3- (methylsulfonyl)phenyl)-1H-indole-5- carboxamide

51

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-5-cyano-2-methyl-1H-indol-3-yl)- N,N-dimethylbenzenesulfonamide

52

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)- 3-(3-(N,N-dimethylsulfamoyl)phenyl)- N,N,2-trimethyl-1H-indole-5- carboxamide

53

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)- 3-(3-(N,N-dimethylsulfamoyl)phenyl)- N,N,2-trimethyl-1H-pyrrolo[3,2- b]pyridine-5-carboxamide

54

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)- N,N,2-trimethyl-3-(3- sulfamoylphenyl)-1H-indole-5- carboxamide

55

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-2-methyl-5-(1,2,4-oxadiazol-3-yl)- 1H-indol-3-yl)-N,N- dimethylbenzenesulfonamide

57

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)- N,N,2-trimethyl-3-(3- ((trifluoromethyl)sulfonyl)phenyl)-1H- indole-5-carboxamide

58

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)- 3-(3-(N,N-dimethylsulfamoyl)phenyl)- N,N,2-trimethyl-1H-indole-5- sulfonamide

59

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-5-(difluoromethyl)-2-methyl-1H- indol-3-yl)-N,N-dimethylbenzene- sufonamide

60

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-5-hydroxy-2-methyl-1H- pyrrolo[3,2-b]pyridin-3-yl)-N,N- dimethylbenzene-sulfonamide

61

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-5-methoxy-2-methyl-1H- pyrrolo[3,2-b]pyridin-3-yl)-N,N- dimethylbenzene-sulfonamide

62

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-5-chloro-2-methyl-1H-indol-3-yl)- N,N-dimethylbenzenesulfonamide

63

(Z)-5-(1-(4-amino-2-fluorobut-2-en-1- yl)-2-methyl-1H-indol-3-yl)-N,N- dimethylpyridine-3-sulfonamide

64

(Z)-5-(1-(4-amino-2-fluorobut-2-en-1- yl)-5-chloro-2-methyl-1H-indol-3-yl)- N,N-dimethylpyridine-3-sulfonamide

65

(Z)-4-(5-chloro-2-methyl-3-(5- (methylsulfonyl)pyridin-3-yl)-1H- indol-1-yl)-3-fluorobut-2-en-1-amine

66

(Z)-5-(1-(4-amino-2-fluorobut-2-en-1- yl)-5-chloro-1H-indol-3-yl)-N,N- dimethylpyridine-3-sulfonamide

67

(Z)-5-(1-(4-amino-2-fluorobut-2-en-1- yl)-6-chloro-2-methyl-1H-indol-3-yl)- N,N-dimethylpyridine-3-sulfonamide

69

(Z)-3-fluoro-4-(5-methoxy-2-methyl- 3-(3-(methylsulfonyl)phenyl)-1H- pyrrolo[3,2-b]pyridin-1-yl)but-2-en-1- amine

70

(Z)-5-(1-(4-amino-2-fluorobut-2-en-1- yl)-5-chloro-2-methyl-1H-indol-3-yl)- N-methylpyridine-3-sulfonamide

71

(Z)-5-(1-(4-amino-2-fluorobut-2-en-1- yl)-5-fluoro-2-methyl-1H-indol-3-yl)- N,N-dimethylpyridine-3-sulfonamide

72

(Z)-5-(1-(4-amino-2-fluorobut-2-en-1- yl)-6-chloro-2-methyl-1H-pyrrolo[3,2- b]pyridin-3-yl)-N,N-dimethylpyridine- 3-sulfonamide

73

(Z)-5-(1-(4-amino-2-fluorobut-2-en-1- yl)-5-chloro-2-methyl-1H-pyrrolo[2,3- b]pyridin-3-yl)-N,N-dimethylpyridine- 3-sulfonamide

75

(Z)-5-(1-(4-amino-2-fluorobut-2-en-1- yl)-4-chloro-2-methyl-1H-indol-3-yl)- N,N-dimethylpyridine-3-sulfonamide

76

(Z)-4-(5-chloro-2-methyl-3-(pyridin-4- yl)-1H-indol-1-yl)-3-fluorobut-2-en-1- amine

77

(Z)-4-(5-chloro-2-methyl-3-(pyridin-3- yl)-1H-indol-1-yl)-3-fluorobut-2-en-1- amine

78

(Z)-6-(1-(4-amino-2-fluorobut-2-en-1- yl)-5-chloro-2-methyl-1H-indol-3-yl)- N,N-dimethylpyridine-2-sulfonamide

79

(Z)-5-(1-(4-amino-2-fluorobut-2-en-1- yl)-5-cyclopropyl-2-methyl-1H-indol- 3-yl)-N,N-dimethylpyridine-3- sulfonamide

80

(Z)-4-(5-chloro-2-methyl-3- (pyrimidin-5-yl)-1H-indol-1-yl)-3- fluorobut-2-en-1-amine

81

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)- N,N,2-trimethyl-3-(pyridin-4-yl)-1H- indole-5-sulfonamide

83

(Z)-5-(1-(4-amino-2-fluorobut-2-en-1- yl)-5-chloro-2-methyl-1H-indol-3- yl)pyridine-3-sulfonamide

84

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)- 2-methyl-3-(pyridin-4-yl)-1H-indole- 5-sulfonamide

85

(Z)-5-(1-(4-amino-2-fluorobut-2-en-1- yl)-2-methyl-5-(trifluoromethoxy)-1H- indol-3-yl)-N,N-dimethylpyridine-3- sulfonamide

86

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)- N,N,2-trimethyl-3-phenyl-1H-indole- 5-sulfonamide

87

(Z)-3-fluoro-4-(2-methyl-5- (methylsulfonyl)-3-phenyl-1H-indol-1- yl)but-2-en-1-amine

88

(Z)-3-fluoro-4-(2-methyl-5- (methylsulfonyl)-3-(pyridin-4-yl)-1H- indol-1-yl)but-2-en-1-amine

92

(Z)-4-(3-(benzo[d][1,3]dioxol-5-yl)-2- methyl-5-(methylsulfonyl)-1H-indol- 1-yl)-3-fluorobut-2-en-1-amine

93

(Z)-3-fluoro-4-(3-(4-fluorophenyl)-2- methyl-5-(methylsulfonyl)-1H-indol- 1-yl)but-2-en-1-amine

94

(Z)-3-fluoro-4-(2-methyl-3-(2- methylpyridin-4-yl)-5- (methylsulfonyl)-1H-indol-1-yl)but-2- en-1-amine

95

(Z)-1-(4-amino-2-fluorobut-2-en-1-yl)- 3-(4-fluorophenyl)-2-methyl-1H- indole-5-sulfonamide

96

(Z)-5-(1-(4-amino-2-fluorobut-2-en-1- yl)-2-chloro-1H-indol-3-yl)-N,N- dimethylpyridine-3-sulfonamide

97

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-2-methyl-5-(methylsulfonyl)-1H- indol-3-yl)-N,N- dimethylbenzenesulfonamide

98

(Z)-3-fluoro-4-(3-(2-methoxypyridin- 4-yl)-2-methyl-5-(methylsulfonyl)-1H- indol-1-yl)but-2-en-1-amine

99

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-2-chloro-1H-pyrrolo[3,2-b]pyridin- 3-yl)-N,N- dimethylbenzenesulfonamide

100

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-2-chloro-5-(methylsulfonyl)-1H- indol-3-yl)-N,N- dimethylbenzenesulfonamide

101

(Z)-4-(3-(2,6-dimethylpyridin-4-yl)-2- methyl-5-nitro-1H-indol-1-yl)-3- fluorobut-2-en-1-amine

102

(Z)-N-(1-(4-amino-2-fluorobut-2-en-1- yl)-3-(2,6-dimethylpyridin-4-yl)-2- methyl-1H-indol-5- yl)methanesulfonamide

103

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-5-(methoxymethyl)-2-methyl-1H- pyrrolo[3,2-b]pyridin-3-yl)-N,N- dimethylbenzenesulfonamide

104

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-2-methyl-5-(methylsulfonamido)- 1H-indol-3-yl)-N,N- dimethylbenzenesulfonamide

105

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-5-(dimethylamino)-2-methyl-1H- pyrrolo[3,2-b]pyridin-3-yl)-N,N- dimethylbenzenesulfonamide

106

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-5-(isopropylsulfonyl)-2-methyl- 1H-indol-3-yl)-N,N- dimethylbenzenesulfonamide

107

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-2,5-dimethyl-1H-pyrrolo[3,2- b]pyridin-3-yl)-N,N- dimethylbenzenesulfonamide

108

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-6-fluoro-2-methyl-1H-pyrrolo[3,2- b]pyridin-3-yl)-N,N- dimethylbenzenesulfonamide

109

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-5-fluoro-2-methyl-1H-pyrrolo[3,2- b]pyridin-3-yl)-N,N- dimethylbenzenesulfonamide

110

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-2-methyl-5-(trifluorometthyl)-1H- pyrrolo[3,2-b]pyridin-3-yl)-N,N- dimethylbenzenesulfonamide

111

(Z)-3-(1-(4-amino-2-fluorobut-2-en-1- yl)-5-(1,1-difluoroethyl-2-methyl-1H- pyrrolo[3,2-b]pyridin-3-yl)-N,N- dimethylbenzenesulfonamide

112

(Z)-4-(2,5-dimethyl-3-(3- (methylsulfonyl)phenyl)-1H- pyrrolo[3,2-b]pyridin-1-yl)-3- fluorobut-2-en-1-amine

113

(Z)-4-(3-(3-(ethylsulfonyl)phenyl)-2- isopropyl-5-methyl-1H-pyrrolo[3,2- b]pyridin-1-yl)-3-fluorobut-2-en-1- amine

114

(Z)-4-(3-(3-(ethylsulfonyl)phenyl)-2,5- dimethyl-1H-pyrrolo[3,2-b]pyridin-1- yl)-3-fluorobut-2-en-1-amine

115

(Z)-3-fluoro-4-(5-(fluoromethyl)-2- methyl-3-(3-(methylsulfonyl)phenyl)- 1H-pyrrolo[3,2-b]pyridin-1-yl)but-2- en-1-amine

116

(Z)-2-(1-(4-amino-2-fluorobut-2-en-1- yl)-2-methyl-3-(3- (methylsulfonyl)phenyl)-1H- pyrrolo[3,2-b]pyridin-5-yl)propan-2-ol

117

(Z)-2-(1-(4-amino-2-fluorobut-2-en-1- yl)-3-(3-(isopropylsulfonyl)phenyl)-2- methyl-1H-pyrrolo[3,2-b]pyridin-5- yl)propan-2-ol

or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, carrier or diluent.

10. A method of inhibiting the amine oxidase activity of LOX, LOXL1, LOXL2, LOXL3 and LOXL4 in a subject in need thereof, comprising administering to the subject an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

11. A compound according to claim 1 of Formula I:

or a stereoisomer or pharmaceutically acceptable salt thereof; wherein:

a is N or CH;

b is N or CR 4 ;

c is N or CR 5 ;

d is N or CR 6 ;

and from 0 to 1 of a, b, c and d are N;

R 1 is selected from the group consisting of hydrogen, halogen and C 1-6 alkyl: wherein each C 3-6 alkyl is a straight or branched chain alkyl;

R 2 is selected from the group consisting of phenyl, pyridinyl and pyrimidinyl; wherein each R 1 is optionally substituted by one or more R 12 ;

R 4 is selected from the group consisting of hydrogen, halogen, —C(O)OR 8 and —C(O)NR 9 R 10 ;

R 5 is selected from the group consisting of hydrogen, halogen, hydroxyl, C 1-6 alkyl, C 3-7 cycloalkyl, —O—C 1-6 alkyl, —CN, —NO 2 , —NR 9 R 10 , —C(O)OR 8 , —C(O)NR 9 R 10 , —S(O 2 )NR 9 R 10 , —NR 9 S(O 2 )R 11 , —S(O 2 )R 11 , tetrazole and oxadiazole; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH and O—C 1-3 alkyl;

R 6 is selected from the group consisting of hydrogen and halogen;

R 8 is selected from the group consisting of hydrogen and C 1-6 alkyl;

R 9 and R 10 are independently selected from the group consisting of hydrogen and C 1-6 alkyl; wherein each C 1-6 alkyl is a straight or branched chain alkyl;

R 11 is C 1-6 alkyl; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl is optionally substituted by one or more halogen; and

R 12 is selected from the group consisting of halogen, C 1-6 alkyl, —O—C 1-6 alkyl, —S—C 1-6 alkyl, —C(O)OR 8 , —C(O)NR 9 R 10 , —S(O 2 )NR 9 R 10 , and —S(O 2 )R 11 ; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl is optionally substituted by one or more halogen.

12. A compound according to claim 1 of Formula I:

or a stereoisomer or pharmaceutically acceptable salt thereof; wherein:

a is CR 3 , b is CR 4 , c is CR 5 and d is CR 6 ; or

a is CR 3 , b is CR 4 , c is CR 5 and d is N; or

a is CR 3 , b is CR 4 , c is N and d is CR 6 ; or

a is CR 3 , b is N, c is CR 5 and d is CR 6 ; or

a is N, b is CR 4 , c is CR 5 and d is CR 6 ;

R 1 is selected from the group consisting of hydrogen and C 1-3 alkyl; wherein each C 1-3 alkyl is a straight or branched chain alkyl;

R 2 is selected from the group consisting of phenyl

2-pyridinyl

3-pyridinyl

4-pyridinyl

and 5-pyrimidinyl

wherein each R 2 is unsubstituted or substituted by one or more R 12 ;

R 3 is hydrogen;

R 4 is selected from the group consisting of hydrogen, halogen, C(O)OH, C(O)OCH 3 , C(O)NH 2 and C(O)N(CH 3 ) 2 ;

R 5 is selected from the group consisting of hydrogen, halogen, hydroxyl, C 1-4 alkyl, cyclopropyl, —O—C 1-4 alkyl, —CN, —NO 2 , —NR 9 R 10 , —C(O)OR 8 , —C(O)NR 9 R 10 , —S(O 2 )NR 9 R 10 , —NR 9 S(O 2 )R 11 , —S(O 2 )R 11 , tetrazole and oxadiazole; wherein each C 1-4 alkyl is a straight or branched chain alkyl; and wherein each C 1-4 alkyl is unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, —OH and O—C 1-3 alkyl;

R 6 is selected from the group consisting of hydrogen and chlorine;

R 6 is selected from the group consisting of hydrogen, methyl and ethyl;

R 9 and R 10 are independently selected from the group consisting of hydrogen and C 1-4 alkyl; wherein each C 1-4 alkyl is a straight or branched chain alkyl;

R 11 is C 1-3 alkyl; wherein each C 1-3 alkyl is a straight or branched chain alkyl; and wherein each C 1-3 alkyl is unsubstituted or substituted by one or more halogen; and

R 12 is selected from the group consisting of halogen, C 1-4 alkyl, —O—C 1-4 alkyl, —C(O)OR 8 , —C(O)NR 9 R 10 , —S(O 2 )NR 9 R 10 , —SCH 3 , and —S(O 2 )R 11 ; wherein each C 1-4 alkyl is a straight or branched chain alkyl; and wherein each C 1-4 alkyl is unsubstituted or substituted by one or more halogen.

13. A compound according to claim 1 of Formula I, wherein:

R 1 is selected from the group consisting of hydrogen, methyl and isopropyl;

R 2 is selected from the group consisting of phenyl

2-pyridinyl

3-pyridinyl

4-pyridinyl

and 5-pyrimidinyl

wherein each R 2 is unsubstituted or substituted by one or more R 12 ;

R 3 is hydrogen;

R 4 is selected from the group consisting of hydrogen, fluorine, chlorine, C(O)OH, C(O)OCH 3 , C(O)NH 2 and C(O)N(CH 3 ) 2 ;

R 5 is selected from the group consisting of hydrogen, fluorine, chlorine, hydroxyl, —CH 3 , —CH 2 F, —CHF 2 , —CF 3 , —CF 2 CH 3 , cyclopropyl, —C(CH 3 ) 2 OH, —CH 2 OCH 3 , —OCH 3 , —OCF 3 , —CN, —NO 2 , —N(CH 3 ) 2 , —C(O)OH, —C(O)OCH 3 , —C(O)OEt, —C(O)N(CH 3 ) 2 , —C(O)NHCH 3 , —C(O)NH i Pr, —C(O)NCH 3 i Pr, —C(O)NH t Bu, —S(O 2 )N(CH 3 ) 2 , —S(O 2 )NH 2 , —NHS(O 2 )CH 3 , —S(O 2 )CH 3 , —S(O 2 ) i Pr, tetrazole and oxadiazole;

R 6 is selected from the group consisting of hydrogen and chlorine; and

R 12 is selected from the group consisting of fluorine, chlorine, —CH 3 , — t Bu, CF 3 , —O—CH 3 , —C(O)OH, —C(O)OEt, —C(O)N(CH 3 ) 2 , —S(O 2 )N(CH 3 ) 2 , S(O 2 )NHCH 3 , —S(O 2 )NH 2 , —S(O 2 )CH 3 , —S(O 2 )Et, —S(O 2 ) i Pr, and —S(O 2 )CF 3 .

14. A compound according to claim 1 , of Formula Ib:

or a pharmaceutically acceptable salt thereof; wherein:

R 1 is selected from the group consisting of hydrogen, halogen and C 1-6 alkyl; wherein each C 1-6 alkyl is a straight or branched chain alkyl;

R 2 is phenyl substituted by one or more R 12 ;

R 3 is hydrogen;

R 4 is selected from the group consisting of hydrogen and halogen;

R 5 is selected from the group consisting of hydrogen, halogen, hydroxyl, C 1-6 alkyl, —O—C 1-6 alkyl, —NR 9 R 10 , —C(O)OR 8 , and —C(O)NR 9 R 10 ; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and wherein each C 1-6 alkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH and O—C 1-3 alkyl;

R 6 is selected from the group consisting of hydrogen and, C 1-6 alkyl;

R 9 and R 10 are independently selected from the group consisting of hydrogen and C 1-6 alkyl; wherein each C 1-6 alkyl is a straight or branched chain alkyl;

R 11 is C 1-6 alkyl; wherein each C 1-6 alkyl is a straight or branched chain alkyl; and

R 12 is selected from the group consisting of —S(O 2 )NR 9 R 10 and —S(O 2 )R 11 .

15. A compound according to claim 14 of Formula Ib, wherein:

R 1 is selected from the group consisting of hydrogen, methyl and isopropyl;

R 2 is phenyl substituted by one or more R 12 ;

R 3 is hydrogen;

R 4 is selected from the group consisting of hydrogen, fluorine and chlorine;

R 5 is selected from the group consisting of hydrogen, fluorine, hydroxyl, —CH 3 , —CH 2 F, —CHF 2 , —CF 3 , —CF 2 CH 3 , —C(CH 3 ) 2 OH, —CH 2 OCH 3 , —OCH 3 , —C(O)OH, —N(CH 3 ) 2 , —C(O)OEt, —C(O)N(CH 3 ) 2 , —C(O)NHCH 3 and —C(O)NH i Pr; and

R 12 is selected from the group consisting of —S(O 2 )N(CH 3 ) 2 , —S(O 2 )NH 2 , —S(O 2 )CH 3 , —S(O 2 )Et and —S(O 2 ) i Pr.

16. The compound of claim 1 having the structure:

or a pharmaceutically acceptable salt thereof.

17. The compound of claim 1 having the structure:

or a pharmaceutically acceptable salt thereof.

18. The compound of claim 1 having the structure:

or a pharmaceutically acceptable salt thereof.